Autologous stem cell transplantation in patients of 70 years and older with multiple myeloma

Results from a matched pair analysis

Research output: Contribution to journalArticle

87 Citations (Scopus)

Abstract

High-dose therapy and autologous stem cell transplant (HDT) have been shown to prolong survival in multiple myeloma (MM) in randomized trials, but only included patients of 65 years or younger. Given the median age at diagnosis of 66 years, it is important to have a better understanding of the outcome of transplantation in the older patients. We identified 33 patients with MM, who were ≥70 years at the time of their HDT. We matched them to a group of 60 patients, 65 years or younger, (two controls for each patient), based on time to transplant, disease status at transplant, Durie-Salmon stage, labeling index, presence of cytogenetic abnormalities, and presence of circulating plasma cells. The median age of the two groups were 55.6 (range, 37.3-64.9) and 71.7 (range 70-75.8) years at transplant. Although more of the older patients received dose reduced melphalan, the overall response rate was similar (97% vs. 98%) as was the median time to progression (28.5 months vs. 17.8 months, P = 0.7) for the elderly group compared to the younger patients. The median overall survival from transplant was not reached for the elderly patient group compared to 53.2 months for the younger patients, P = 0.7. HDT is feasible in selected patients with multiple myeloma over 70 years. The toxicity of transplant as well as the outcome appears comparable to younger patients. Patients with MM should not be excluded from HDT solely on the basis of their chronological age.

Original languageEnglish (US)
Pages (from-to)614-617
Number of pages4
JournalAmerican Journal of Hematology
Volume83
Issue number8
DOIs
StatePublished - Aug 2008

Fingerprint

Matched-Pair Analysis
Stem Cell Transplantation
Multiple Myeloma
Transplants
Melphalan
Survival
Salmon
Plasma Cells
Chromosome Aberrations
Stem Cells

ASJC Scopus subject areas

  • Hematology

Cite this

@article{c1cbbb489f1d4986b16111a678832961,
title = "Autologous stem cell transplantation in patients of 70 years and older with multiple myeloma: Results from a matched pair analysis",
abstract = "High-dose therapy and autologous stem cell transplant (HDT) have been shown to prolong survival in multiple myeloma (MM) in randomized trials, but only included patients of 65 years or younger. Given the median age at diagnosis of 66 years, it is important to have a better understanding of the outcome of transplantation in the older patients. We identified 33 patients with MM, who were ≥70 years at the time of their HDT. We matched them to a group of 60 patients, 65 years or younger, (two controls for each patient), based on time to transplant, disease status at transplant, Durie-Salmon stage, labeling index, presence of cytogenetic abnormalities, and presence of circulating plasma cells. The median age of the two groups were 55.6 (range, 37.3-64.9) and 71.7 (range 70-75.8) years at transplant. Although more of the older patients received dose reduced melphalan, the overall response rate was similar (97{\%} vs. 98{\%}) as was the median time to progression (28.5 months vs. 17.8 months, P = 0.7) for the elderly group compared to the younger patients. The median overall survival from transplant was not reached for the elderly patient group compared to 53.2 months for the younger patients, P = 0.7. HDT is feasible in selected patients with multiple myeloma over 70 years. The toxicity of transplant as well as the outcome appears comparable to younger patients. Patients with MM should not be excluded from HDT solely on the basis of their chronological age.",
author = "Kumar, {Shaji K} and Dingli, {David M} and Martha Lacy and Angela Dispenzieri and Hayman, {Suzanne R.} and Buadi, {Francis K.} and Rajkumar, {S Vincent} and Litzow, {Mark R} and Morie Gertz",
year = "2008",
month = "8",
doi = "10.1002/ajh.21191",
language = "English (US)",
volume = "83",
pages = "614--617",
journal = "American Journal of Hematology",
issn = "0361-8609",
publisher = "Wiley-Liss Inc.",
number = "8",

}

TY - JOUR

T1 - Autologous stem cell transplantation in patients of 70 years and older with multiple myeloma

T2 - Results from a matched pair analysis

AU - Kumar, Shaji K

AU - Dingli, David M

AU - Lacy, Martha

AU - Dispenzieri, Angela

AU - Hayman, Suzanne R.

AU - Buadi, Francis K.

AU - Rajkumar, S Vincent

AU - Litzow, Mark R

AU - Gertz, Morie

PY - 2008/8

Y1 - 2008/8

N2 - High-dose therapy and autologous stem cell transplant (HDT) have been shown to prolong survival in multiple myeloma (MM) in randomized trials, but only included patients of 65 years or younger. Given the median age at diagnosis of 66 years, it is important to have a better understanding of the outcome of transplantation in the older patients. We identified 33 patients with MM, who were ≥70 years at the time of their HDT. We matched them to a group of 60 patients, 65 years or younger, (two controls for each patient), based on time to transplant, disease status at transplant, Durie-Salmon stage, labeling index, presence of cytogenetic abnormalities, and presence of circulating plasma cells. The median age of the two groups were 55.6 (range, 37.3-64.9) and 71.7 (range 70-75.8) years at transplant. Although more of the older patients received dose reduced melphalan, the overall response rate was similar (97% vs. 98%) as was the median time to progression (28.5 months vs. 17.8 months, P = 0.7) for the elderly group compared to the younger patients. The median overall survival from transplant was not reached for the elderly patient group compared to 53.2 months for the younger patients, P = 0.7. HDT is feasible in selected patients with multiple myeloma over 70 years. The toxicity of transplant as well as the outcome appears comparable to younger patients. Patients with MM should not be excluded from HDT solely on the basis of their chronological age.

AB - High-dose therapy and autologous stem cell transplant (HDT) have been shown to prolong survival in multiple myeloma (MM) in randomized trials, but only included patients of 65 years or younger. Given the median age at diagnosis of 66 years, it is important to have a better understanding of the outcome of transplantation in the older patients. We identified 33 patients with MM, who were ≥70 years at the time of their HDT. We matched them to a group of 60 patients, 65 years or younger, (two controls for each patient), based on time to transplant, disease status at transplant, Durie-Salmon stage, labeling index, presence of cytogenetic abnormalities, and presence of circulating plasma cells. The median age of the two groups were 55.6 (range, 37.3-64.9) and 71.7 (range 70-75.8) years at transplant. Although more of the older patients received dose reduced melphalan, the overall response rate was similar (97% vs. 98%) as was the median time to progression (28.5 months vs. 17.8 months, P = 0.7) for the elderly group compared to the younger patients. The median overall survival from transplant was not reached for the elderly patient group compared to 53.2 months for the younger patients, P = 0.7. HDT is feasible in selected patients with multiple myeloma over 70 years. The toxicity of transplant as well as the outcome appears comparable to younger patients. Patients with MM should not be excluded from HDT solely on the basis of their chronological age.

UR - http://www.scopus.com/inward/record.url?scp=49149101596&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=49149101596&partnerID=8YFLogxK

U2 - 10.1002/ajh.21191

DO - 10.1002/ajh.21191

M3 - Article

VL - 83

SP - 614

EP - 617

JO - American Journal of Hematology

JF - American Journal of Hematology

SN - 0361-8609

IS - 8

ER -